A phase 1/2 clinical trial of DG 12P1 for Wilson disease
Latest Information Update: 13 Jan 2020
At a glance
- Drugs DG 12 P1 (Primary)
- Indications Hepatolenticular degeneration
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2020 New trial record
- 07 Jan 2020 According to a Deep Genomics media release, company plans to obtain data from this trial in 2021.